miRagen Therapeutics
News from miRagen Therapeutics now, and the biopharmaceutical firm has made two new appointments:
Christoper Mori – who has previously worked for Ambit, GSK and Agensys –has joined the firm as Chief Business Officer.
Dr. Aimee Jackson will serve as Director of Target Development. Jackson has over ten years of experience in the industry and previously worked for Rosetta Inpharmatics/Merck in Seattle.
“The additions of Chris and Aimee strengthen our management team and further facilitate our ability to develop promising microRNA-targeting therapeutic candidates,” said Dr. William Marshall, President and CEO of mirage.
ire, Angus spearheaded and achieved numerous initiatives and helped to transform the company into the global industry leader that it is today,” said Questcor’s Chairman Virgil Thompson.
